Literature DB >> 11737409

Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline.

D Smith1, I Gow, R Colebunders, I Weller, S Tchamouroff, J Weber, F Boag, G Hales, S Adams, G Patou, D A Cooper.   

Abstract

In a randomized placebo controlled trial 304 HIV infected patients with CD4 cell counts below 350 cells/microL received therapeutic vaccination with: alum placebo (Group I, n = 102), p24-VLP 500 microg (Group II, n = 101) or p24-VLP 1000 microg (Group III, n = 101) p24-VLP monthly for six months. Over one year the average change in CD4 cell count did not differ significantly between groups (-32, -40 and -52 cells per microL respectively). There was also no difference between groups in progression to CDC category B or C events, or in adverse events. Therapeutic vaccination with p24-VLP does not affect CD4 cell decline in patients with advanced HIV infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11737409     DOI: 10.1046/j.1468-1293.2001.00080.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  5 in total

Review 1.  Prospects for immune reconstitution in HIV-1 infection.

Authors:  N Imami; F Gotch
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

Review 2.  Self-assembling protein nanoparticles in the design of vaccines.

Authors:  Jacinto López-Sagaseta; Enrico Malito; Rino Rappuoli; Matthew J Bottomley
Journal:  Comput Struct Biotechnol J       Date:  2015-11-26       Impact factor: 7.271

3.  Retrospective Proteomic Analysis of Cellular Immune Responses and Protective Correlates of p24 Vaccination in an HIV Elite Controller Using Antibody Arrays.

Authors:  Suneth S Perera; Bin Wang; Arturo Damian; Wayne Dyer; Li Zhou; Viviane Conceicao; Nitin K Saksena
Journal:  Microarrays (Basel)       Date:  2016-06-02

Review 4.  Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.

Authors:  Natasha Kushnir; Stephen J Streatfield; Vidadi Yusibov
Journal:  Vaccine       Date:  2012-11-06       Impact factor: 3.641

Review 5.  Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1.

Authors:  Yong Gao; Chanuka Wijewardhana; Jamie F S Mann
Journal:  Front Immunol       Date:  2018-02-28       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.